Skip to content

Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus

Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02644395
Acronym
TT
Enrollment
49
Registered
2015-12-31
Start date
2013-01-18
Completion date
2016-12-19
Last updated
2017-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Kidney Transplantation

Brief summary

Background: Calcineurin inhibitors (CNIs) are the most commonly used immunosuppressive drugs to prevent rejection after kidney transplantation. However, the efficacy of preventing rejection comes at the cost of important side-effects. Among the most common side-effects is hypertension. Hypertension after kidney transplantation is clinically relevant, because it increases the risk of cardiovascular disease and is associated with increased graft loss and recipient mortality. The mechanism of CNI-induced hypertension is incompletely understood and, therefore, the treatment is currently empiric. These and other investigators recently showed that CNIs cause salt-sensitive hypertension by activating a sodium transporter in the kidney, namely the thiazide-sensitive sodium chloride cotransporter. Hypothesis: The investigators hypothesize that thiazide diuretics are non-inferior to calcium channel blockers (CCBs) (currently usually the treatment of choice) for the treatment of CNI-induced hypertension. Objective: To compare the blood pressure response to thiazide diuretics and CCBs in patients with CNI-induced hypertension. Study design: Single-center, randomized cross-over trial. Study population: Kidney transplant recipients with a good functioning allograft (eGFR \> 30 ml/min) who are hypertensive (daytime systolic blood pressure \> 140 mm Hg) and who do not have proteinuria (\< 1 g/day). Intervention: Patients will be randomized to receive chlorthalidone (12.5 mg once daily, if needed titrated to 25 mg once daily) or amlodipine (5 mg once daily, if needed titrated to 10 mg once daily). Main study parameters/endpoints: 24-hour blood pressure recording. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Both drugs have long been registered for the treatment of hypertension. The side-effect profile of both drugs is considered to be equal. The burden of the study for the patients are blood pressure measurements using 30-minute automated blood pressure measurement and 24-hour ambulatory blood pressure measurement.

Interventions

DRUGChlorthalidone

Drug

DRUGAmlodipine

Drug

Sponsors

Erasmus Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Kidney transplant recipients using tacrolimus * Average daytime SBP \> 140 mm Hg (ABPM) * eGFR \> 30 ml/min (MDRD)

Exclusion criteria

* Use of glucocorticoids, co-trimoxazole, diuretics * Pregnancy * Serum sodium \< 136, serum potassium \< 3.5 * Proteinuria \> 1 g/day

Design outcomes

Primary

MeasureTime frame
Average daytime SBP8 weeks

Secondary

MeasureTime frame
Laboratory parameters8 weeks
Side effects8 weeks

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026